平衡晶体液与生理盐水用于危重症患者液体复苏:系统评价与荟萃分析及试验序贯分析
该系统评价与荟萃分析检索MEDLINE、Cochrane Central和EMBASE至2018年10月,纳入9项比较平衡晶体液与生理盐水用于危重症患者的随机对照试验。汇总分析显示两组死亡率(RR=0.93,95%CI 0.86-1.01,P=0.08)、急性肾损伤发生率(RR 0.94,95%CI 0.88-1.00,P=0.06)和肾脏替代治疗使用率(RR 0.94,95%CI 0.69-1.27,P=0.67)均无显著差异。试验序贯分析未提供确凿证据。作者结论认为平衡晶体液与生理盐水相比未降低死亡率、严重急性肾损伤风险或肾脏替代治疗使用率,需要进一步大型随机临床试验证实或反驳该发现。
要点
- 9项RCT汇总显示,平衡晶体液与生理盐水组死亡率无显著差异(RR=0.93,95%CI 0.86-1.01,P=0.08)。
- 急性肾损伤发生率两组无显著差异(RR 0.94,95%CI 0.88-1.00,P=0.06)。
- 肾脏替代治疗使用率两组无显著差异(RR 0.94,95%CI 0.69-1.27,P=0.67)。
- 试验序贯分析未提供确凿证据,作者结论认为需进一步大型随机临床试验证实或反驳。
适用人群与场景
- 接受晶体液治疗的危重症患者(纳入的9项RCT人群)。
研究设计与关键结果
- 研究类型:系统评价与荟萃分析,纳入9项随机对照试验(RCT),检索MEDLINE、Cochrane Central和EMBASE至2018年10月。
- 主要终点死亡率:平衡晶体液组与生理盐水组无显著差异(RR=0.93,95%CI 0.86-1.01,P=0.08)。
- 次要终点急性肾损伤发生率:两组无显著差异(RR 0.94,95%CI 0.88-1.00,P=0.06)。
- 次要终点肾脏替代治疗使用率:两组无显著差异(RR 0.94,95%CI 0.69-1.27,P=0.67)。
- 试验序贯分析(TSA)未提供确凿证据。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,纳入9项随机对照试验(RCT)。
- 试验序贯分析未提供确凿证据。
- 局限:作者结论指出需要进一步大型随机临床试验证实或反驳该发现。
对床旁实践的改变
- 作者结论认为,在危重症接受晶体液治疗的患者中,与生理盐水相比,使用平衡晶体液未降低死亡率、严重急性肾损伤风险或肾脏替代治疗使用率。
- 作者结论指出需要进一步大型随机临床试验证实或反驳该发现。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Fluid resuscitation is a fundamental component of the management of critically ill patients, but whether choice of crystalloid affects patient outcomes remains controversial. Therefore, we performed this meta-analysis to compare the efficacy and safety of balanced crystalloids with normal saline.
METHODS: We searched the MEDLINE, Cochrane Central and EMBASE up to October 2018 to identify randomized controlled trials (RCTs) that compared balanced crystalloids versus normal saline in critically ill patients. The primary outcome was mortality. The secondary results were the incidence of acute kidney injury (AKI) and risk of receiving renal replacement therapy (RRT). Two authors independently screened articles based on the inclusion and exclusion criteria. The meta-analysis was conducted using Revman 5.3, trial sequential analysis (TSA) 0.9 and STATA 12.0.
RESULTS: Nine RCTs were identified. The pooled analyses showed that there were no significant differences in mortality (relative risk (RR) = 0.93, 95% confidence interval (CI) = 0.86, 1.01, P = 0.08), incidence of AKI (RR 0.94, 95% CI 0.88, 1.00, P = 0.06) or RRT use rate (RR 0.94, 95% CI 0.69, 1.27, P = 0.67) between balanced crystalloids and normal saline groups. However, TSA did not provide conclusive evidence.
CONCLUSIONS: Among critically ill patients receiving crystalloid fluid therapy, use of a balanced crystalloid compared with normal saline did not reduce the mortality, risk of severe AKI or RRT use rate. Further large randomized clinical trials are needed to confirm or refute this finding.
TRIAL REGISTRATION: A protocol of this meta-analysis has been registered on PROSPERO (registration number: CRD42018094857).
参考来源
- Liu C, Lu G, Wang D, et al. Balanced crystalloids versus normal saline for fluid resuscitation in critically ill patients: A systematic review and meta-analysis with trial sequential analysis. Am J Emerg Med. 2019. PMID: 30852043. doi:10.1016/j.ajem.2019.02.045
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。